Because of a possible risk of contracting a rare brain disease that is sometimes fatal, Tysabri is generally recommended for US patients who are not responding to or cannot tolerate an alternative MS therapy.
Biogen Idec seeks regulatory OK’s for wider use of a multiple sclerosis drug
By Chris Reidy| Globe Staff January 16, 2013
Read it all, now.
Don't miss any of your favorite stories again. Read the stories that matter to you as much as you want, whenever you want when you subscribe to BostonGlobe.com.
Get full access today for just 99¢